Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec;32(13):9731-9740.
doi: 10.1245/s10434-025-18196-7. Epub 2025 Sep 26.

Assessing the Annual Risk of Recurrence Following Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Diffuse Malignant Peritoneal Mesothelioma Patients

Julien Péron  1   2 , Ismail Essadi  3 , Pascal Rousset  4   5 , Laurent Villeneuve  5   6 , Nazim Benzerdjeb  5   7 , Diane Goéré  8 , Isabelle Sourrouille  9 , Olivia Sgarbura  10 , Gwenaël Ferron  11 , Marc Pocard  12   13 , Frédéric Dumont  14 , Jean-Marc Bereder  15 , Cécile Brigand  16 , Olivier Glehen  5   17 , Vahan Kepenekian  18   19 ; RENAPE
Collaborators, Affiliations

Assessing the Annual Risk of Recurrence Following Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Diffuse Malignant Peritoneal Mesothelioma Patients

Julien Péron et al. Ann Surg Oncol. 2025 Dec.

Abstract

Background: Selected diffuse malignant peritoneal mesothelioma (DMPM) patients may be radically treated with complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Two thirds of them recur with the possibility of iterative CRS-HIPEC and/or systemic chemotherapy. The postoperative follow-up management is based on scarce data. The recurrence profile was explored in a large national database to challenge the standard follow-up protocol.

Methods: Consecutive, pathologically proven, epithelioid DMPM patients from the RENAPE database, treated with complete CRS-HIPEC were included in this analysis. Patients with more than 5 years of follow-up were divided into long-term control group (event-free), early relapse group (event within 2 years), and intermediate relapse group. Survival distributions were estimated by the Kaplan-Meier method.

Results: Overall, 288 patients met the inclusion criteria (95% epithelioid, median PCI 18) with 197 followed-up more than 5 years, divided into long-term control (57 patients), intermediate relapse (34 patients), and early relapse (106 patients). After a median follow-up time of 71 months, the median relapse-free survival (RFS) was 37.2 months (95% confidence interval 26.4-52.8 months). The recurrence risk was highest during the first 2 years (36.8% of patients recurred) and remained around 10% per year until year 8. In the multivariate analysis, age <60 and PCI <17 were independent factors of better RFS. Interestingly, 27% of recurring patients presented distant metastases.

Conclusions: These results strengthen current follow-up guidelines, while also suggesting a close follow-up between years 5 and 8. No subgroup of patients or biomarkers have been identified to personalize follow-up.

Keywords: CRS; DMPM; Follow-up; HIPEC; Peritoneal mesothelioma.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Olivier Glehen—Consultant for Gamida.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/CAAC.21492 . - DOI - PubMed
    1. Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005. Cancer Causes Control CCC. 2009;20(6):935–44. https://doi.org/10.1007/S10552-009-9328-9 . - DOI - PubMed
    1. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18(6):985–90. https://doi.org/10.1093/ANNONC/MDL345 . - DOI - PubMed
    1. Karpes JB, Shamavonian R, Dewhurst S, et al. Malignant peritoneal mesothelioma: an in-depth and up-to-date review of pathogenesis, diagnosis, management and future directions. Cancers. 2023. https://doi.org/10.3390/CANCERS15194704 . - DOI - PubMed - PMC
    1. Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18(5):827–34. https://doi.org/10.1093/ANNONC/MDL428 . - DOI - PubMed

MeSH terms

LinkOut - more resources